The clinical syndrome of frontotemporal dementia (FTD) is characterised by progressive changes in behaviour, personality and/or language, with relative preservation of memory (Refs 1, 2, 3). Clinical subtypes include the frontal (behavioural) variant (fvFTD) and two forms of primary progressive aphasia (PPA): primary non-fluent aphasia (PNFA) and semantic dementia (SD) (Refs 1, 2). FTD is often associated with an extrapyramidal movement disorder (parkinsonism or corticobasal syndrome) or with motor neuron disease (MND) (Refs 4, 5) . FTD accounts for 5 -15% of all dementia and is the second commonest cause in the presenile age group (Refs 6, 7). A family history of similar disease is present in 25 -50% of patients, indicating a significant genetic influence (Refs 8, 9, 10). It should be noted that there are currently two conventions used for the nomenclature of this clinicopathological syndrome. Here, we use the one that is more popular in North America, in which FTD is used as the general term for the clinical syndrome (including all behavioural and language variants) and the term frontotemporal lobar degeneration (FTLD) is reserved for the associated pathology. However, in the UK, FTLD is often used as the general term for both the clinical and the pathological entities, whereas FTD refers only to the clinical subtype in which behavioural abnormalities predominate. We recognise that this situation is confusing; however, both terminologies are currently in wide use and there is no consensus as to which is more appropriate.
The molecular genetic basis of FTD is heterogeneous. Autosomal dominant FTD may be caused by mutations in several genes, including those encoding the microtubuleassociated protein tau (MAPT) (Refs 11, 12, 13), progranulin (GRN) The neuropathology associated with clinical FTD is also heterogeneous (Ref. 21). Relatively selective degeneration of the frontal and temporal lobes (frontotemporal lobar degeneration, FTLD) is a consistent feature, which correlates with the main clinical manifestations. As with many other neurodegenerative conditions, the pathology of most cases of FTD includes the presence of abnormal intracellular protein accumulations. Traditionally, these inclusion bodies were demonstrated with special histochemical staining techniques, such as silver impregnation methods. Eponymous and syndromic names were used for clinical syndromes associated with a specific morphology and anatomical distribution of cellular inclusions. However, in many cases, these clinicopathological correlations turned out to be imperfect. Modern laboratory techniques, such as immunohistochemistry, have allowed the biochemical composition of the pathological changes to be more readily determined. In recent years, it has become popular to classify FTLD pathology based on the presumed molecular defect, in the belief that this most closely reflects the underlying pathogenic process (Ref. 21) .
In this review, we will use the molecular-based system of nosology and nomenclature recommended in a recent consensus paper (Ref. 22 ). The term FTLD will be used as the general terminology for pathological conditions that are commonly associated with clinical FTD, and major subdivisions will be designated by the protein abnormality that is presumed to be pathogenic or most characteristic (Table 1) 
FTLD-tau Tau protein
Tau is a microtubule-associated phosphoprotein (MAP) that is abundantly expressed in both the central and peripheral nervous system. By promoting microtubule (MT) assembly and stability, tau plays a fundamental role in maintaining neuronal integrity and axoplasmic transport (Refs 23, 24). The tau gene (MAPT) is located on chromosome 17q21 and has two major haplotypes, H1 and H2, which are defined by a set of single nucleotide polymorphisms and a 238 base pair deletion in intron 9 (Ref. 25). The H2 haplotype is also associated with an inversion of a 900 kb region that includes MAPT (Ref. 26). MAPT contains 16 exons, 11 of which encode the major tau protein isoforms (Ref. 27 ). Through alternative mRNA splicing of exons 2, 3 and 10, a set of six isoforms, ranging from 352 to 441 amino acids, are generated in the adult human brain. Exons 9 to 12 encode four microtubulebinding motifs, which are imperfect repeats of 31 or 32 amino acids, in the C-terminal half of the tau molecule. It is these binding domains that mediate the interaction between tau and MTs. Alternative splicing of exon 10 generates tau isoforms with either three (exon 10 missing) or four (exon 10 present) repeat domains, known as 3R and 4R tau, respectively (Fig. 1a 
FTLD-tau (PiD)
PiD is the clinicopathological prototype of FTD (Refs 33, 34, 35). The most distinctive gross pathological feature is marked atrophy of the frontal and anterior temporal lobes, also known as 'knife-edge' lobar atrophy (Fig. 2a) .
The main histological features consist of severe neuronal loss, ballooned neurons (Pick cells) and pathognomonic spherical argyrophilic neuronal inclusions, called Pick bodies (PBs) (Fig. 2b) . PBs are found mainly in (Fig. 2c) , which are fairly specific for PSP, as well as thorn-shaped astrocytes, coiled bodies in oligodendrocytes and neuropil threads, all of which are also Tau isoforms and tau gene mutations found in other tauopathies. Neurofibrillary tangles typically have a round or globose appearance (Fig. 2d) 
FTLD-tau (CBD)
CBD is an increasingly recognised neurodegenerative disease with both motor and 
FTDP-17T
In However, some MAPT mutations result in a clinical phenotype that more closely resembles PiD, CBD, PSP, AGD or AD. In all cases of FTDP-17T, the neuropathology includes various types of fibrillar tau pathology. Some mutations are associated with inclusions in both neurons and glia (Fig. 2i) , whereas others lead to a predominance of neuronal tau pathology. Depending on the mutation site, tau aggregates can be composed predominantly of 3R or 4R tau isoforms, or a mixture of both. MAPT mutations are located in the coding region or in the intron flanking the alternatively spliced exon 10 (Fig. 1b) and fall into two main functional categories: those that affect the alternative splicing of tau pre-mRNA, and those whose primary effect is at the protein level. The mechanisms by which the various MAPT mutations impair tau functions and generate filamentous tau inclusions are beyond the scope of this review, but they have recently been reviewed elsewhere (Refs 28, 66, 67).
FTLD-tau due to other gene abnormalities
In addition to FTDP-17T, there remain many familial FTLD-tau cases for which no MAPT mutation has been discovered. Recently, an interesting association has been described between familial FTLD-tau and presenilin 1 (PS-1). Mutations in the genes encoding PS-1 and PS-2 (PSEN1 and PSEN2) account for the majority of early-onset familial AD (Ref. 68 
Normal function of TDP-43
TDP-43 is a protein comprising 414 amino acids, which is encoded by the TARDBP gene on chromosome 1 (Fig. 3a) 92) . TDP-43 is highly conserved, ubiquitously expressed and predominantly localised to the nucleus. It consists of two RNA-recognition motifs and a glycine-rich C-terminal region (Fig. 3a) . Recent studies have shown that TDP-43 continuously shuttles between the nucleus and cytoplasm -a process partially regulated by nuclear localisation signal (NLS) and nuclear export signal (NES) motifs (Refs 93, 94) . In addition to its well-characterised role in regulation of expert reviews 
TDP-43 is the major pathological protein in FTLD-TDP
As demonstrated in the initial reports and rapidly confirmed by numerous subsequent studies, antibodies against TDP-43 have proven to be the most sensitive and specific tool to detect all of the different types of the ub-ir pathology found in most cases of FTLD-U, including the NCIs, DNs and neuronal intranuclear inclusions (NIIs) (Fig. 3b, d) 
Pathological subtypes of FTLD-TDP
FTLD-TDP pathology is heterogeneous with respect to the morphology and laminar distribution of pathological inclusions, leading to the description of four distinct pathological subtypes (Fig. 3d) 
Familial FTLD-TDP FTD due to GRN mutations
Although many of the original FTDP-17 kindreds were found to have MAPT mutations (see section on FTLD-tau), there remained several families with FTD linked to the same region of chromosome 17 in which no MAPT mutation could be identified and some of these were known to have FTLD-U rather than tau pathology. This enigma was resolved in 2006, with the discovery of mutations in GRN, which is located just 1.7 Mb centromeric to MAPT (Refs 14, 15). Progranulin (PGRN) is a multifunctional secreted protein that probably serves as a neurotrophic growth or survival factor, with functions in wound healing and inflammation (Refs 110, 111, 112 . Except for the Y374X truncation mutation, all others are missense mutations, mostly in exon 6, which effect highly conserved amino residues in the C-terminal region of TDP-43. Elucidating the functional consequences of ALS-causing TARDBP mutations is likely to also provide important insights into the mechanism of neurodegeneration in FTLD-TDP. One current hypothesis is that TARDBP mutations might interfere with protein -protein interaction, thereby affecting intracellular transport or crucial transcriptional and splicing activities. Alternatively, the mutations might increase the generation of CTFs, promote the aggregation of TDP- 43 and/or result in abnormal phosphorylation (Refs 129, 131, 135 ).
FTLD-UPS
Although initial data suggested that all FTLD-U cases are characterised by TDP-43 pathology, recent follow-up studies have demonstrated that there are some cases in which the pathological inclusions are only detectable with markers of the ubiquitin proteasome system (FTLD-UPS), in which the pathological ubiquitinated protein(s) is still unknown (Refs 100, 104, 142, 143) . The most common subtype of FTLD-UPS, representing 10-20% of all FTLD-U cases, was recently described in detail (Refs 144, 145) . The highly unusual and consistent clinical and pathological features of these cases suggest that they represent a newly recognised, discrete entity and the term atypical FTLD-U (aFTLD-U) was introduced. The clinical phenotype is sporadic, early-onset FTD with severe progressive behavioural and personality changes in the absence of aphasia or significant motor features. In addition to frontotemporal atrophy, severe degeneration of the anterior striatum and hippocampal sclerosis are common findings in aFTLD-U. TDP-43-negative, ubiquitin-positive and p62-positive NCIs are most abundant in the frontal and temporal neocortex and hippocampus (Fig. 4a) . However, the most intriguing pathological feature is the presence of NIIs in the dentate granule cells and cortical pyramidal neurons with a unique morphology, where they appear as elongated straight or curved bars or thick twisted filaments (Fig. 4b, c) . The immunohistochemical profile of these NIIs is also unusual and different from the NCIs, because they are reactive for ubiquitin but not for p62 (Fig. 4d) .
Familial FTD linked to chromosome 3 (FTD-3), due to mutations in CHMP2B (Ref. 17) has also recently been shown to have FTLD-UPS pathology (Ref. 146) . So far, four families have been identified with different CHMP2B mutations (AD&FTD Mutation database: http:// www.molgen.ua.ac.be/FTDmutations). CHMP2B belongs to the chromatin-modifying protein/ charged multivesicular body protein family and is a component of ESCRT-III (endosomal sorting complex required for transport III), a complex involved in the degradation of surface receptor proteins and the formation of endocytotic multivesicular bodies. Although previous reports failed to detect abnormal protein deposits in brains of patients with FTD-3, a recent study demonstrated the presence of granular NCIs that were immunoreactive for ubiquitin and p62, but negative for TDP-43 and tau, predominantly in the dentate granule cells of the hippocampus (Fig. 4e) (Ref. 146) . The neuropathological findings in NIFID are heterogeneous, but have a number of consistent features (Refs 148, 150, 151, 152, 153, 154, 155, 156, 157) . Chronic degenerative changes may affect a variety of cortical and subcortical regions, with the frontal and temporal lobes and caudate nucleus most consistently and severely involved. Several types of neuronal inclusions are found. The most common are small round Pick-body-like inclusions that are well-defined, slightly eosinophilic or basophilic and rarely argyrophilic (Fig. 5a ). These are variably immunoreactive for ubiquitin, NF and a-internexin but negative for tau, a-synuclein and TDP-43 ( Fig. 5b) (Ref. 149) . The ultrastructure is a combination of electrondense granular material and dispersed short filaments (Refs 156, 158, 159) . These are numerous in affected regions of cerebral neocortex, hippocampus and in select subcortical regions. Hyaline conglomerate inclusions are less frequent, and appear as irregular, multilobulated masses that often compress the nucleus (Fig. 5c ). They are weakly eosinophilic, with a glassy, filamentous appearance and sometimes have a dense, brightly eosinophilic core. These stain intensely with the Bielschowsky silver method and are more consistently and intensely immunoreactive for IFs (Fig. 5d) . The ultrastructure is compact, interlacing bundles of filaments (Ref. 158) . NCI with other morphologies may also be present, and there are often IF-immunoreactive swollen axons. A less consistent feature is the presence of eosinophilic NIIs that are intensely immunoreactive for ubiquitin but generally not reactive for IFs (Fig. 5e) (Refs 149, 153, 154, 158) .
FTLD-IF
Neuronal IFs include the triplet of light (68 kDa 
BIBD
BIBDisatermthat has beenusedfora small number of clinically and pathologically heterogeneous cases, in which the common finding is neuronal cytoplasmic inclusions that are basophilic with haematoxylin and eosin stain (Fig. 5f) The molecular basis of frontotemporal dementia 
Outstanding research questions
Despite the enormous gains made over the past few years in our understanding of the molecular basis of FTD, many fundamental issues are still unresolved. The FTLD gene on chromosome 9 remains to be identified and there is probably at least one other genetic cause of familial FTLDtau. The normal functions of PGRN and TDP-43 in the nervous system need to be clarified, as do the mechanisms by which mutations in GRN, 
